Legal Representation
Attorney
Fidel Nwamu
USPTO Deadlines
Next Renewal Deadline
1087 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2022-06-28)
Due Date
June 28, 2028
Grace Period Ends
December 28, 2028
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
50 events| Date | Code | Type | Description |
|---|---|---|---|
| Jun 28, 2022 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Jun 28, 2022 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| May 21, 2022 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| May 20, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| May 20, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| May 20, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| May 20, 2022 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| Apr 1, 2022 | CNRT | W | SU - NON-FINAL ACTION - WRITTEN |
| Apr 1, 2022 | GNRT | O | NON-FINAL ACTION E-MAILED |
| Apr 1, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Mar 2, 2022 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Mar 2, 2022 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE |
| Feb 8, 2022 | EISU | I | TEAS STATEMENT OF USE RECEIVED |
| Feb 8, 2022 | IUAF | S | USE AMENDMENT FILED |
| Aug 20, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Aug 18, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Aug 18, 2021 | EXT3 | S | SOU EXTENSION 3 FILED |
| Aug 18, 2021 | EX3G | S | SOU EXTENSION 3 GRANTED |
| Jun 23, 2021 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
| Feb 18, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Feb 16, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Feb 16, 2021 | EXT2 | S | SOU EXTENSION 2 FILED |
| Feb 16, 2021 | EX2G | S | SOU EXTENSION 2 GRANTED |
| Aug 5, 2020 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Aug 5, 2020 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Aug 5, 2020 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Jul 23, 2020 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Jul 21, 2020 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Jul 21, 2020 | EXT1 | S | SOU EXTENSION 1 FILED |
| Jul 21, 2020 | EX1G | S | SOU EXTENSION 1 GRANTED |
| Feb 18, 2020 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Dec 24, 2019 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Dec 24, 2019 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Dec 4, 2019 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Nov 14, 2019 | RCCK | S | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION |
| Nov 14, 2019 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Nov 13, 2019 | ALIE | A | ASSIGNED TO LIE |
| Apr 21, 2019 | RCSC | S | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED |
| Oct 9, 2018 | CNSL | R | SUSPENSION LETTER WRITTEN |
| Oct 9, 2018 | GNSL | S | LETTER OF SUSPENSION E-MAILED |
| Oct 9, 2018 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Oct 5, 2018 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Oct 4, 2018 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Oct 4, 2018 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Aug 8, 2018 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Aug 8, 2018 | GNRT | F | NON-FINAL ACTION E-MAILED |
| Aug 8, 2018 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Aug 7, 2018 | DOCK | D | ASSIGNED TO EXAMINER |
| Jul 13, 2018 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Jul 12, 2018 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 042
Conducting evaluations in the field of pharmaceuticals; pharmaceutical product development and evaluation services; pharmaceutical research and development; research and development of pharmaceuticals for the treatment of cancer; research and development of vaccines and medicines; technical research in the field of pharmaceutical studies; scientific research services, namely, collection of specific molecular and genomic data for analytical and clinical purposes, for the treatment of cancer and other diseases and disorders and for individuals' responses to drug treatments; providing scientific analysis in the field of next generation sequencing (NGS), namely, the analysis and interpretation of genomic data obtained from cancer patients
First Use Anywhere:
Sep 17, 2016
First Use in Commerce:
Sep 17, 2016
Classification
International Classes
042